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Abstract
Three-dimensional cell culture has many advantages over monolayer cultures, and spheroids have been hailed as the best
current representation of small avascular tumours in vitro. However their adoption in regular screening programs has been
hindered by uneven culture growth, poor reproducibility and lack of high-throughput analysis methods for 3D. The
objective of this study was to develop a method for a quick and reliable anticancer drug screen in 3D for tumour and human
foetal brain tissue in order to investigate drug effectiveness and selective cytotoxic effects. Commercially available ultra-low
attachment 96-well round-bottom plates were employed to culture spheroids in a rapid, reproducible manner amenable to
automation. A set of three mechanistically different methods for spheroid health assessment (Spheroid volume, metabolic
activity and acid phosphatase enzyme activity) were validated against cell numbers in healthy and drug-treated spheroids.
An automated open-source ImageJ macro was developed to enable high-throughput volume measurements. Although
spheroid volume determination was superior to the other assays, multiplexing it with resazurin reduction and phosphatase
activity produced a richer picture of spheroid condition. The ability to distinguish between effects on malignant and the
proliferating component of normal brain was tested using etoposide on UW228-3 medulloblastoma cell line and human
neural stem cells. At levels below 10 mM etoposide exhibited higher toxicity towards proliferating stem cells, whereas at
concentrations above 10 mM the tumour spheroids were affected to a greater extent. The high-throughput assay
procedures use ready-made plates, open-source software and are compatible with standard plate readers, therefore offering
high predictive power with substantial savings in time and money.
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Introduction
Rising attrition rates of over 95% in drug discovery despite
growing Research and Development budgets remain one of the
biggest problems of the pharmaceutical industry [1]. This is
especially true in the field of brain tumours where drugs need to
circumvent a number of barriers to reach their target. The most
common reasons for drug failure are lack of efficacy on one hand
and safety risks on the other. Preclinical disease models of
increased biorelevance are needed so that drug performance and
toxicity in-vitro matches in-vivo behaviour [2]. Cancer drug
discovery still relies largely on culturing tumour cell lines in two-
dimensional monolayers to test the effects of therapeutics. This
simple reductionist model offered by monolayers bears little
resemblance to the in-vivo situation and the results obtained rarely
coincide with the outcomes of clinical trials [3]. Our interest in
improving drug delivery to the brain [4] has pointed the need for
establishing superior preclinical models to characterise the safety
and efficacy of cancer treatment.
Three-dimensional cell culture has been reported to match
many aspects of the true behaviour of tumours [5]. Culturing cells
in 3D accounts for the complex cell-cell, cell-extracellular matrix
interactions, and the formation of nutrient and oxygen gradients
which tumours exhibit in-vivo [6]. Methods of culturing cells in
3D [7,8] include polarised cultures using transwell inserts,
multicellular spheroids, bioreactors, matrix embedded cells,
scaffold based systems, hollow-fibre bioreactors and organotypic
slices. Multicellular tumour spheroids can be cultured in a high-
throughput format and offer the closest representation of small
avascular tumours in-vitro [9,10]. They possess the necessary cell
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and matrix interactions, exhibit nutrient and oxygen gradients,
and express genes similar to the ones expressed by tumours in-vivo
[11,12]. Spheroids can be formed using a number of methods:
spontaneous aggregation, bioreactors, spinner flasks, hanging-
drop, liquid overlay, matrix embedding, polymeric scaffolds and
microfluidic devices [13].
Although the advantages of using spheroids in cancer research
have been known since the 1970s [14] monolayer cultures are still
the primary form of cell based screening. That is because three-
dimensional cultures have been notorious for their slow growth,
expensive maintenance and the difficulties associated with viability
determination in 3D. In order to match the ease and convenience
of 2D assays the ideal 3D screen should be quick, reproducible and
amenable to high-throughput using standard methods such as
phase and fluorescent microscopy and standard plate readers. Two
methods claim to have all of the above qualities and aim to replace
monolayer cultures as the methods of choice for anticancer drug
screens: hanging drop plates and overlay cultures. The hanging
drop plates developed by InSphero [15] and 3D Biomatrix [16]
utilise the 96 and 384 well format and rely on growing the
spheroid in a hanging drop. Their main drawback is the need to
transfer the spheroid to a normal 96 or a 384-well plate in order to
probe viability and proliferation. The liquid overlay method
overcomes these challenges and utilises either in-house prepared
poly-hydroxyethyl methacrylate [17] and agarose [18] coated
plates or commercially available ultra-low attachment plates [19].
Spheroids grown using the liquid overlay method are scaffold free
and the extracellular matrix that keeps them together is naturally
secreted by the cells [20]. Although this culture method can
produce spheroids with diameters of 100 mm to over 1 mm the
preferred size for analysis is 300–500 mm. This ensures that the
right pathophysiological gradients of oxygen and nutrients are
present along with a core of hypoxic quiescent cells thought to be
responsible for the increased chemo- and radioresistance of
spheroids and solid tumours [18,21,22]. With all requirements
met, liquid overlay is the most suitable method to grow
reproducible 3D cell cultures of uniform well-defined shape
accessible for automated high-throughput screens and data
mining.
The replacement of monolayers by 3D cell culture will require
validated, cost-effective, high-throughput compatible methods to
assay spheroid growth, viability and the effects of treatment. Over
50 years of spheroid research has shown that the growth of cells in
three dimensions is only advantageous in a practical sense if
analysis is rapid and reliable in high throughput and with standard
equipment. Since liquid overlay cultures are stationary and
produce a single spheroid in the middle of each well, tracking
growth can be easily accomplished with phase-contrast light
microscopy. Images of the spheroids in each well can be collected
and analysed using specialised equipment like the Celigo
cytometer [19] or commercial software programmes [18,19,23].
However the investment in new equipment or image editing
software can be seen as a hindrance to the mainstream
implementation of spheroid research. Therefore we chose to work
with the open-source software ImageJ and developed an in-house
automated macro for spheroid analysis to facilitate image analysis
within the scientific community. Apart from volume, cell viability
within the spheroid can be assessed using metabolic assays like the
reduction of Resazurin [24] or measuring ATP [19]. These assays
are convenient and quick however they have not been properly
validated yet for use in 3D cultures. Friedrich et al [25] have
validated and encouraged the use of the acid phosphatase assay to
determine viability and claimed that metabolic assays may not be
equally suited for the task.
This paper describes work aimed at developing a biorepresen-
tative three-dimensional cytotoxicity screen for human tissues with
conventional microplate assays. The therapeutic and neurotoxic
potentials of the model drug etoposide for brain tumours were
investigated using spheroid volume, metabolism and acid phos-
phatase activity. The brain tumour medulloblastoma cell line
UW228-3 was chosen to represent the pharmacological target of
treatment and human foetal brain tissue spheroids were selected to
determine possible off-target effects on the developing brain.
Materials and Methods
1. Materials
Dulbecco’s Phosphate Buffered Saline (PBS), Dulbecco’s
Modified Eagle’s Medium - high glucose (DMEM), Ham’s
nutrient mixture F12, L-Glutamine solution 200 mM, Penicillin/
Streptomycin solution (10,000 units penicillin and 10 mg strepto-
mycin/mL), Heparin, Sodium pyruvate, Trypsin 106 solution 4-
nitrophenyl phosphate disodium salt hexahydrate and etoposide
were obtained from Sigma-Aldrich (Dorset,UK).
Foetal Bovine Serum (FBS), N2 supplement, B27 supplement
serum-free supplement, DMEM without phenol red, basic human
Fibroblast Growth Factor (bFGF), human recombinant Epidermal
Growth Factor (EGF), Accutase and 0.4% Trypan Blue Stain
solution were supplied by Invitrogen (Paisley, UK). Resazurin was
sourced from Acros Organics (Loughborough, UK)
Ultra low attachment (ULA) 96-well round bottom plates were
obtained from Corning (Amsterdam, The Netherlands)
2. Cell lines and culture
All experiments were performed in standard cell culture
conditions at 37uC and 5% CO2.
UW228-3 medulloblastoma cell line [26] was obtained from
Prof. Silber (University of Washington, Seattle, USA) with the help
of the Children’s Brain Tumour Research Centre at the University
of Nottingham. Tumour cells were routinely cultured for less than
20 passages in monolayer in media containing DMEM (41.5%),
Ham’s F12 (41.5%), L-Glutamine solution (1%), Sodium pyruvate
(1%) and FCS (15%). Subculturing was performed using 0.025%
Trypsin in Ca2+ and Mg2+ free PBS solution for 5 minutes.
Foetal human brain tissue was received from the Joint MRC/
Wellcome Trust (grant # 099175/Z/12/Z, Ethics committee
approval 08/H0906/21+5, Health Research authority NRES
Committee North East - Newcastle & North Tyneside 1) Human
Developmental Biology Resource (www.hdbr.org). The tissue was
rinsed, mechanically dissociated into a single cell suspension and
cultured in non-treated flasks to form stem cell enriched neuro-
spheres [27]. The Neural stem cell (NSC) defined serum-free
media was made using DMEM (47.5 ml), Ham’s F12 (47.5 ml),
B27 (2 ml), N2 (1 ml), L-Glutamine (200 mM, 1 ml), Penicillin/
Streptomycin solution (1 ml), hEGF (20 mg/ml, 100 ml), bFGF
(10 mg/ml, 100 ml), Heparin (5 mg/ml, 100 ml) for 100 ml.
Neurospheres were subcultured for less than 15 passages. Briefly,
when the neurospheres reached a diameter of 100–300 mm they
were collected in a polystyrene centrifuge tube, rinsed with PBS,
resuspended in Accutase (1 ml) and agitated for 5 minutes at 37uC
followed by mechanical dissociation with a blue (1 ml) tip on a
Gilson pipette. The suspension was diluted with fresh NSC media
and centrifuged at 300 g for 5 minutes. The cell pellet was
resuspended in Ca2+ and Mg2+ free PBS (200 ml) with a yellow
(200 ml) tip on a Gilson pipette and the final single-cell suspension
diluted to the desired concentration with NSC media.
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3. Spheroid production
Ultra low attachment (ULA) 96-well round bottom plates are
pre-coated with a hydrophilic polymer that prevents attachment
and triggers the formation of a single spheroid per well. Using
these plates, spheroids of different size were formed in NSC media
with both cell types using single-cell suspensions with a constant
volume of 200 ml and concentrations ranging from 250 to 200 000
cells per ml. The plates were centrifuged lightly at 100 g for
3 minutes after seeding to bring the cells closer together, minimize
cell death and encourage the formation of a single spheroid
[17,19]. Old media was carefully exchanged with fresh (150 ml) on
days 3 and 5, taking care not to disturb the spheroids, and
spheroids were cultured for 7 days before final analysis.
4. Phase microscopy and image analysis
Images of all spheroids were taken daily for growth determi-
nation and on day 3, day 5 and day 7 in cytotoxicity experiments
using an Olympus CKX41 microscope with a 106 objective and
an attached Olympus E330 camera. The scale of images was
determined using a calibration slide. Images were analysed using
the open-source software ImageJ (Fiji package) and a macro was
written to automate the process (Macro S1). The macro works on
whole folders of images, converts them to black and white, and
uses the Yen thresholding algorithm [28]. It proceeds to clean any
artefacts from the image, fills holes in the spheroid, separates it
from debris and determines the area, maximum and minimum
Ferret diameter of the spheroid. The macro also saves a copy of
the file of each analysed image with a blue outline of the spheroids
it has detected and an additional file with the numerical
measurements for the whole folder. Variation in the area
determination between the algorithm and manual measurement
was found to be less than 5%. Data from the macro was analysed
in Excel and the measured area (S) of the 2D projection of the
spheroids was used to calculate the radius (R~
ﬃﬃﬃ
S
p
r
) and the
volume (V =
4
3
pR3) of an equivalent sphere [29].
5. Growth kinetics
UW228-3 cells were seeded in ULA plates at concentration
ranging from 250 cells to 200 000 cells/ml and NSCs were seeded
at 1000 to 200 000 cells/ml. They formed spheroids which were
photographed daily and analysed for metabolic and acid
phosphatase activity on day 7. Spheroid volume increase was
calculated by dividing the difference in spheroid volume between
day 7 and day 1 by the volume on day 1 (Vincrease% = (Vday72
Vday1)*100/Vday1).
6. Cytotoxicity experiments
Single cell suspensions were seeded in ULA plates at concen-
trations determined by the growth kinetics to produce spheroids
between 300–500 mm in size on day 3 (25 k/ml for UW228-3 and
50 k/ml for NSCs). Old medium (150 ml) was carefully removed
on day 3 and replaced with medium containing etoposide ranging
from 0.03 mM to 300 mM from a 50 mM etoposide stock solution
in DMSO. The drug exposure time was 48 h (until day 5) when
medium was exchanged twice with fresh etoposide-free medium
(150 ml), reducing drug concentrations to 1/16th of initial levels.
Afterwards spheroids were incubated for a further 48 h until day 7
when their viability was assessed using spheroid volume, resazurin
metabolism and acid phosphatase activity. Negative control
spheroids were cultured with 0.2% DMSO as vehicle and used
to determine 100% viability while the positive control ones were
exposed to 25% DMSO and represented 0% viability. The
300 mM etoposide concentration contained a higher level of
DMSO (0.6%) and was used along with the positive control to
elicit complete cell death and represent the bottom of the dose-
response curve. A row of wells with media only and no cells was
included to exclude contamination and verify that the positive
control is functioning properly. Six replicate spheroids per
condition were exposed to a total of 9 levels of etoposide in each
experiment and the displayed results are the average of at least
three independent experiments. In the case of neural stem cells,
tissue from three different foetuses was used in the different
experiments.
7. Resazurin reduction assay
A stock solution of resazurin (440 mM in PBS), was aliquotted
and stored at 218uC. Frozen aliquots were thawed and kept in the
fridge before use, protected from light. On the day of analysis a
working solution of 60 mM resazurin was prepared in NSC
medium. Medium in the wells was partially replaced with working
solution (150 ml) and the plates were placed back in the incubator.
Fluorescence was measured with an excitation wavelength of
530 nm and emission 590 nm on a Galaxy Fluostar plate reader at
4 h after dye addition.
8. Acid phosphatase assay
Acid phosphatase (APH) activity was determined using 4-
nitrophenyl phosphate as described by Friedrich [18,25]. The
APH assay was performed on the same spheroids after the
Resazurin assay. Resazurin was removed using two washes with
PBS to leave 100 ml, APH assay buffer (100 ml), containing para-
Nitrophenylphosphate (PNPP, 2 mg/ml), TritonX (0.1% vol/vol)
in Citrate buffer (0.1M), was added and the plates incubated for
90 minutes at 37uC. Afterwards NaOH (1M, 10 ml,) was added to
the wells and the absorbance was read at 405 nm with a reference
wavelength of 630 nm on an Asys Expert 96-well plate reader.
9. Spheroid dissociation and cell counts
After volume and Resazurin assays, spheroids from the growth
kinetics and cytotoxicity experiments were dissociated and
counted. Dissociation was carried out after washing the spheroids
twice with Ca2+ and Mg2+ free PBS (150 ml), removal of PBS,
followed by 20 minute incubation with Accutase (50 ml) at 37uC.
Mechanical dissociation with a multichannel pipette was carried
out to form a single cell suspension and all six wells representing
the same conditions were pooled in a microcentrifuge tube and
centrifuged at 300 g for 5 minutes. The supernatant was taken off
and the cells were resuspended in PBS (200 ml). Cell counts were
performed using the Orflo Moxi Z automated thin-film sensor cell
Coulter counter. The Moxi Z software has an internal curve-fitting
algorithm which finds the healthy part of the cell population and
expresses overall viability based on cell size reduction and debris
content without the use of special reagents.
10. Assay Validation
Resazurin, Acid phosphatase and Volume determination assays
were optimised and evaluated based on their Z-factor [30], Signal
window [31] and Coefficient of Variation.
Z-factors were calculated using the equation:
Z~1{
3  (SDsamplezSDcontrol)
Meansample{Meancontrol
In growth experiments, the standard deviation and mean of the
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readings for medium-only wells were used as control. Z9-factors,
reported in cytotoxicity assays, have been calculated by substitut-
ing the values for positive and negative control in the above
equation. Signal window (SW) was defined as:
SW~
Meansample{Meancontrol{3  (SDsamplezSDcontrol)
SDsample
Coefficient of variation was calculated as CV%~
SD
Mean
|100
Acceptance criteria [32] were set at Z-factor.0.4, SW.2 and
CV%,20%. They were used along with the biological consider-
ations to optimise the cell density needed for the cytotoxicity
screens. Plate uniformity was assessed on whole plates seeded with
25 k/ml UW228-3 and 50 k/ml NSCs cells. Phase contrast
photographs were taken on day 3 after seeding and the variation in
volume of the resultant spheroids was examined (acceptance
criteria CV,20%). Signal variability validation was carried out on
the 7th day of the etoposide exposure experiments. Non-
normalised assay readouts at each etoposide concentration were
compared to the 25% DMSO positive control and Z-factor, SW
and CV were calculated for each condition.
11. Data analysis
Results from volume, Resazurin reduction, APH activity and
cell number measurements were analysed in MS Excel and
Graphpad Prism 6. In assay validation experiments, readings for
each assay were normalised so that the highest reading represents
100% and the reading for cell-free media 0%. Data was fitted to a
straight line using Prism’s least squares algorithm. In cytotoxicity
experiments, readings were normalized so that untreated control
has 100% viability and the readings for the positive control were
taken as 0% viability. Dose response curves were fitted using either
the four-parameter logistic equation for monophasic dose response
(UW228-3) or the biphasic dose-response equation (NSCs) in
Prism. Results are displayed as mean 6 SD. Combined IC50
values from several experiments were derived by pooling the data
together and analysing all runs from a single assay as one, using
the logIC50 means (geometric means of IC50s) or by employing
Prism’s extra-sum-of-squares F-test to fit a curve with a common
logIC50 between experimental runs as described in [33]. There
were n = 6 replicates for each condition in each individual
experiment and displayed data represent the mean of at least
three independent experiments.
Results and Discussion
Both neural stem cells and UW-228-3 tumour cell lines formed
one centrally positioned spheroid in each well of the round bottom
96-well plates. Single spheroid formation and cell survival were
encouraged with a light centrifugation which brought the cells
together. Centrifugation reduced cell loss and yielded viable
spheroids within 24 h with as few as 50 and up to 40000 cells.
Centrifugation is reported to encourage paracrine signalling and
suppress apoptosis in the early stages of spheroid formation [34].
The spheroids were cultured for 72 h before the first media
change to allow for the formation of extracellular matrix and
spheroid compaction. UW 228-3 medulloblastoma cells formed
spheroids ranging from 92 mm (50 cells) to 840 mm (406103 cells)
in diameter and coefficient of variation CVdiameter #5% (n = 6).
The spheroids formed by NSCs were 150 mm (200 cells) to
730 mm (406103 cells) in diameter and CVdiameter #4% (n = 6).
The culture in ULA plates was quick and reproducible and did not
differ much from a regular monolayer screen except for the fact
that the spheroids were left for 3 days before drug addition.
Stem cell and tumour spheroids exhibited different size
increases over the 7 day duration of the experiment (Figure 1).
Both cell types showed a similar relationship between seeding
concentration and proliferation capacity. Very low seeding
densities (50–100cells/well) resulted in little growth, intermediate
ones (1000 and 5000 cells/well for NSCs and UWs respectively)
proliferated the most, while seeding high cell numbers yielded big
spheroids whose growth was hindered by the constant volume of
media and the geometry of the well. Similar findings have been
reported by Mori et al. [34], who argued that paracrine
enhancement of Notch signalling in intermediate sized spheroids
is one of the reasons for their enhanced growth. NSC media
contains EGF and bFGF which stimulate the division of stem cells
explaining their higher proliferation capacity compared to
UW288-3. The decreased proliferation of the tumour cell line
can be a consequence of having a lower percentage of stem-like
cells responsive to EGF and FGF within the tumour spheroids and
lack of interactions with normal tissue, which could enhance
tumour growth [35]. Nevertheless, tumour spheroids increased
their volume by 170% showing a slow and steady growth pattern
close to their behaviour in-vivo.
Apart from investigating growth patterns, these initial experi-
ments were used to probe the suitability of spheroid volume,
metabolic activity and acid phosphatase activity to predict
numbers of viable cells within spheroids of various sizes of both
cell types. Spheroids were grown for 7 days and their ability to
reduce resazurin, acid phosphatase activity (performed on a
second twin plate) and volume were determined as described
above. Spheroids were dissociated and the resultant cell counts
were plotted against assay response (Figure 2). The graphs clearly
show that for healthy spheroids, over the range of 160–800 mm in
diameter, volume correlates best with the number of healthy cells
within a spheroid. As spheroids grow in size the cells in the core
have less access to nutrients and oxygen, become firstly hypoxic
and afterwards necrotic. Although the core of the spheroid
becomes less populated the opposite is true for the periphery
where a layer of densely packed cells is established [25,36,37]. This
phenomenon can explain the relatively constant relationship
between volume and cell number of the spheroids in this
experiment. However this relationship will need to be confirmed
Figure 1. Spheroid volume increase of NSC and UW228-3 cells
as a function of initial seeding number. Volume increase
%= 100*(Vday72Vday1)/Vday1. NSCs grew more in a week than UW cells,
reaching maximum growth increase of 600% for seeding 1000 cells per
spheroid, whereas the maximum growth increase for tumour cells was
around 170% for 2000–5000 cells/spheroid.
doi:10.1371/journal.pone.0103817.g001
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and validated for every new cell type used and the relevant
spheroid size as spheroids of .500 mm in diameter will have a
more pronounced necrotic core and deviate from linearity [23,38].
With the use of our specially written ImageJ macro (Macro S1)
we were able to increase greatly the speed of image processing and
facilitate the use of spheroid volume in rapid automated screens.
The algorithm estimates spheroid volume using the area of the
spheroid and fits the equivalent radius to that of an equivalent
sphere. The spheroids do not need to be perfect spheres as the
estimation is roughly valid for ellipsoids of width/length ratio up to
1.5 [29]. Moreover initial studies utilising the maximum and
minimum Ferret diameter and estimating the volume of an
ellipsoid (data not shown) exhibited greater variation due to
thresholding artefacts affecting automatic measurements. The
macro is optimised for phase-contrast images and requires manual
magnification calibration at line 6. However the code can be easily
adapted to suit applications like fluorescence imaging by altering
the thresholding mechanism and using additional macros distrib-
uted with the free Fiji version of ImageJ [39,40].
Acid phosphatase activity correlated almost linearly with cell
number and volume for UW228-3 and NSCs. As evident from
Figure 2A, in healthy NSC cells volume and acid phosphatase
can be used interchangeably as markers of viability. Moreover, the
correlation coefficient was above 0.9 for spheroids of both cell
types indicating an excellent linear relationship. Although the
APH method is faster and easier than photographing and
computing spheroid volume it requires lysing the cells and has
to be the final assay in a high-content analysis program.
The reduction of Resazurin, also known as Alamar Blue, by
metabolically active cells was the final method for viability
determination. Resazurin reduction was proportional to the
number of cells within NSC and UW spheroids. However this
method had a higher variability than volume and APH activity
and the r2 values for Resazurin were the lowest of the three
methods tested. Nevertheless, the Resazurin assay has the
advantages of being non-toxic to the cells at the concentrations
and time of exposure, can be used many times on the same cells
and can also be multiplexed with other assays. Our initial concern
with using Resazurin was that it may only detect metabolically
active cells and miss hypoxic quiescent cells in the core of the
spheroid. Cells in the periphery of the spheroid have good access
to oxygen and nutrients and are actively dividing. Therefore their
metabolism is much more rapid than the cells in the core of the
spheroid where ATP levels have dropped to the minimum and
metabolism is much slower [41–43]. In this way smaller spheroids
were expected to be more metabolically active and appear more
‘alive’ than bigger spheroids which have a significant quiescent
population [25]. This effect was observed in the NSC population
(Figure 2A) and led to minor overestimation of viability for
smaller spheroids.
Apart from viability validation the growth studies were also used
to select the seeding concentration for both cell types that resulted
in spheroid diameter at day 3 of around 400–500 mm, namely
5000 and 10000 cells/well for UW228-3 and NSCs respectively.
The size was chosen because it fits the requirements for gradients
of oxygen, nutrients and proliferation rate that are essential for a
biorelevant spheroid screen [18].
Additionally, Z-factor, Signal window and Coefficient of
variation were compared for the assays in both cell types at each
seeding cell density after 7 days of culture in order to determine
their suitability for high throughput screening. Both the Z-factor
and Signal window take into account the variability of empty
(media-only) control wells as well as the sample wells and provide a
useful benchmark for hit-detection fitness in high-throughput
screening (HTS). The coefficient of variation provides information
on assay variability and can uncover pipetting problems especially
at low seeding densities.
In UW228-3 cells (Figure 3) spheroid volume determination
provided a sufficient working range for HTS when spheroids were
seeded at density higher than 1000 cells/well. This high sensitivity
is due to the ability of the thresholding macro algorithm to
recognise empty wells and report them as such. Although the APH
and Resazurin assays were also able to detect spheroids at the
1000cells/well, they excelled in all indicators at seeding concen-
tration of more than 5000 UW228-3 cells/well. This along with
the biorelevance arguments discussed above showed that seeding
density of 5000 cells/well or more is optimal for cytotoxicity
screening.
Neural stem cells produced spheroids with narrower size
distribution and could be used in screens at even lower seeding
Figure 2. Volume, resazurin and acid phosphatase as methods to determine viability in NSC and UW228-3 spheroids. A. NSCs
spheroids, diameter 200–800 mm. B. UW228-3 tumour spheroids, diameter of 160–700 mm. Both cell types were grown as spheroids for a week and
then probed for volume, metabolic and acid phosphatase activity. Spheroids were enzymatically dissociated and normalised assay response plotted
against the number of cells per spheroid in order to compare the three assays. Normalised assay responses from three independent experiments
were pooled together, plotted and the linearity of each method was examined.
doi:10.1371/journal.pone.0103817.g002
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densities (Figure 4). Volume and APH had generally higher Z-
factor and SW than Resazurin as their signals had lower
variability. All parameters were within specification for spheroids
initially made up of more than 2000 cells. Nevertheless a seeding
density of 10000cells/well was chosen as it produced neurospheres
of similar size to the tumour spheroids at the day of drug
application.
The purpose of developing this screening assay was to compare
the effects of etoposide on neural stem cells and tumours and to
determine if it offers any selectivity in their action. The
topoisomerase inhibitor etoposide [44] was picked as the drug of
choice because it has shown promising activity against medullo-
blastoma in vivo [45] and has been investigated as a potential
candidate for intrathecal therapy [4,46]. The main therapeutic
merit of etoposide is seen as a way of reducing craniospinal
radiation in young medulloblastoma patients in whom it could
reduce the serious side effects associated with radiotherapy [47].
Plate uniformity was assessed prior to etoposide addition at day
3. Spheroid uniformity was evaluated by the variability of spheroid
diameter and volume along the whole plate in at least three plates
Figure 3. Assay characterisation using Z-factors, Signal Window (SW) and Coefficient of variation (CV) for UW228-3 cells. Z-factors
(A–C), Signal window (D–F) and Coefficient of variation (G–I). Acceptance criteria Z-factor.0.4, SW.2 and CV,20% were colour coded so that values
above the green lines meet quality criteria whereas values above the red line fail. Dotted line at 5000 cells represents chosen seeding density for
spheroid cytotoxicity screening.
doi:10.1371/journal.pone.0103817.g003
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on different dates (Figure S1). The mean diameter for UW
spheroids was 422 mm with a coefficient of variation of 4–7%
between 7 plates of 33 to 66 spheroids each. NSC spheroids had a
mean diameter of 463 mm and CV of 3% between 3 plates
containing 66 spheroids each. The coefficient of variation for
volume measurements was around 9% for NSC and ranged from
6 to 22% for UW228-3 cells with only one plate exceeding the
20% limit. Several outliers were identified and were attributed to
deficiencies in pipetting technique and equipment. Therefore the
Graphpad Prism ROUT method was used to eliminate outliers
before testing for normality of volume distribution. The D’Agos-
tino-Pearson omnibus K2 test showed a normal distribution of the
cleaned volume data in all but one case. Even without outlier
elimination a one-tailed t-test, for a sample of 6 replicates from the
plate population, with a= 0.05 will have 1-b= 74% power to
detect a 20% viability drop in UW228-3 cells (CV 15%) and 99%
power to detect the same viability drop in NSC cells (CV 9%) [48].
After the plate uniformity assessment, the tissues were exposed
to etoposide for 48 h, followed by a 48 h period in plain media for
the drug effects to fully manifest. The total duration time of the
screen was 7 days and spheroid viability was determined using
volume, acid phosphatase, metabolic activity and dissociated
Figure 4. Assay characterisation using Z-factors, Signal Window (SW) and Coefficient of variation (CV) for NSCs. Z-factors (A–C),
Signal window (D–F) and Coefficient of variation (G–I). Acceptance criteria Z-factor.0.4, SW.2 and CV,20% were colour coded so that
values above the green lines meet quality criteria whereas values above the red line fail. Dotted line at 10000 cells represents chosen seeding density
for spheroid cytotoxicity screening.
doi:10.1371/journal.pone.0103817.g004
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spheroid cell counts (Figure 5). The dose-response curves for
UW228-3 (Figure 5A) spheroids produced by reduction in
volume (Figure S2), metabolism or acid phosphatase activity
were very similar and the three assays appeared to be equally
suited for a spheroid screen in this cell line. Viability determined
by cell counts for dissociated spheroids was comparable to that
calculated using the other assays up to drug concentrations
affecting spheroid health. At pharmacologically active concentra-
tions there appears to be an overestimation of cell death after
subjecting the spheroids to enzymatic and mechanical dissociation.
Apoptotic and stressed cells may be more sensitive to the
dissociation process and that could be the reason behind the fast
drop in viability estimated using cell numbers. Regarding
phosphatase activity it is worth noting that at high drug
concentrations the APH assay fails to detect any enzymatic
activity in UW228-3 cells, whereas there was still some signal
present from the Resazurin assay. Initially the volume measure-
ments for the tumour cell line at high drug doses were thought to
be less reliable because the spheroids were surrounded by a cloud
of debris and dying cells and it was not possible to distinguish the
dead cells from the living ones without bias (Figure 6, panels A–
C). Similar observations about the difficulties in volume measure-
ments have also been reported by Friedrich [25]. However it was
soon apparent that the debris and apoptotic cells can easily be
washed out by exchanging the media twice with PBS (Figure 6,
panels A9–C9). This greatly facilitated automated image analysis
by improving the speed and accuracy of spheroid size measure-
ments.
Contrary to the UW228-3 monophasic response, foetal brain
tissue-derived NSCs (Figure 5B, Figure S3) had a biphasic
etoposide dose-response curve. Initially there was a very sharp
decrease in viability down to 50% at concentrations approaching
0.3 mM. Beyond this concentration point the viable cell fraction
decreased only slightly when etoposide concentrations were
increased from 0.3 to 3 mM. This was followed by a moderate
decrease in viability down to around 5% at the highest drug
concentrations. The biphasic behaviour of the NSC spheroids is a
sign that there are at least two distinct cell populations within the
microtissues. The gradients of nutrients and oxygen can trigger
differentiation into glia and neurons which would have a different
sensitivity to the parent stem cells. Moreover, there could be an
indigenous population of partially-differentiated progenitor cells in
the foetal brain tissue which have a limited division potential and
differ from the true stem cell phenotype [37,49].
Viability estimates for NSC spheroids using the suite of four
methods varied more than those for the UW228-3 cell line. That
was probably due to the heterogeneous character of the tissue
derived from foetal brains. Viability estimates using cell number
and volume were of similar magnitude and were both generally
lower compared to the values determined by resazurin and APH.
Despite the fast drop in spheroid volume and cell counts, the
metabolic activity as determined by resazurin reduction, dropped
more slowly. The innate features of apoptosis, which starts with
cell shrinkage while metabolic activity is not impaired, can give a
possible explanation to these differences. Treatment with increas-
ing concentrations of etoposide would push some of the cells in the
spheroid towards apoptosis, leading to cell shrinkage and
reduction in spheroid volume. It could also make the affected
cells more sensitive to enzymatic digestion and the effects of
mechanical agitation, leading to cell loss upon spheroid dissoci-
ation. However the apoptotic cells within intact spheroids would
remain metabolically active, continue to reduce Resazurin and
register as alive in the assay. Similarly to our findings, Chan et al
[50] noted a difference in viability estimation between various
cytotoxicity assays being developed for high throughput screening
in 2-D assays. In some experiments using etoposide they showed
that ATP and metabolism-based assays underestimated cytotox-
icity compared to cell number. They have attributed this to
increase in cell volume and mitochondrial mass relative to cell
number. Other studies have also demonstrated increased ATP
content and mitochondrial activity during etoposide treatment and
have linked this with apoptosis [51], autophagy [52] or AMPK
activation [53]. The viability measurements using acid phospha-
tase enzymatic activity against PNPP were the highest of all four
assays. That was most pronounced for high etoposide concentra-
tions between 10 and 100 mM where the fraction of apoptotic cells
was the highest. Acid phosphatase is a digestive enzyme and has a
role in cell death, apoptosis and autophagy [54]. The extensive cell
kill induced at high etoposide concentrations could be triggering
an increase of specific and non-specific phosphatase activity in
stem cells. The biphasic curve also hints at the possibility that there
are two cell populations with different drug sensitivity and
enzymatic activity. The first population which is very sensitive to
Figure 5. Dose-response curves for UW228-3 and NSCs spheroids exposed to increasing concentrations of etoposide. Normalized
viability is expressed as volume, resazurin reduction, acid phosphatase activity and cell number. Data is pooled from at least three separate
experiments.
doi:10.1371/journal.pone.0103817.g005
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etoposide has a relatively low phosphatase expression and a more
resistant second population which expresses higher APH activity.
The precision of the four assays for UW228-3 cells (Figure 7)
was assessed by comparing the 95% confidence intervals (CIs) for
each experimental IC50 determination to the geometric mean
values for all IC50 determinations along with the associated 95%
confidence interval of the mean. The geometric mean of all
experiments was calculated using the logIC50 values which have a
distribution closer to normal as opposed to IC50 results which
tend to be skewed [55]. This approach was chosen after
comparing it to the methods of pooling the data into one or using
Prism’s extra-sum-of-squares F-test to compare IC50 values of
dose-response curve fits [33] (Figure S4). It was deemed useful as
a graphical aid to assess between-run variability and gave slightly
broader CIs as seen in the case for Cell counting for example.
Overall, resazurin and volume assays were superior to APH and
direct cell counting. Although estimating viability using volume
exhibited the smallest confidence intervals for the individual
measurements, the IC50 values between runs varied more than
those for resazurin. Moreover resazurin had the narrowest 95%
confidence interval for the mean of the five separate runs.
For assay precision in neurospheres, only Resazurin and
Volume gave IC50 values that were reproducible and had
reasonable 95% confidence intervals varying less than one order
of magnitude (Figure 8). Volume determinations yielded the
tightest CIs with the highest level of precision out of the four
assays. The determinations of IC50_1 and IC50_2 from APH and
Cell counting varied over two orders of magnitude and were not
included in the graph. The high level of variability in cell number
estimation is due to the extra number of steps required to
dissociate the spheroids and the possibility for cell loss during the
process of mechanical and enzymatic cell separation. The APH
assay, on the other hand, may have been affected by non-specific
substrate cleavage at high etoposide concentrations leading to
overestimation of viability and poor non-linear regression fits.
Additionally, signal uniformity assessment was performed on all
etoposide treated plates to determine variability at each concen-
tration. This test is similar to the signal variability assessment in
the NCAT’s Assay guidance manual [32] but instead of only using
high, medium and low signal points we have used the whole dose-
response curve to determine Z-factors (Figure S5) and Coefficient
of Variation (Figure S6). The Z9-factors of all three assays were
Figure 6. Phase-contrast microscope image of UW228-3 spheroids exposed to increasing concentrations of etoposide. Panels A–C
show intact UW228-3 spheroids with a halo of debris and dead cells at high drug doses impeding image analysis. Panels A9–C9 capture the same
UW228-3 spheroids after PBS rinse. Controls were cultured in plain media, concentration of etoposide is given in mM and scale bar applies for all
images.
doi:10.1371/journal.pone.0103817.g006
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higher than 0.5 for the medium-only control wells and remained
above the threshold of 0.4 even up to the IC50 concentration of
3 mM. This shows that the assays are well within their optimal
working range for high-throughput screening at viabilities down to
50%. Although normalising the data did not affect the results of
non-linear regression as described by Motulsky and Christopoulos
[33], it was found to change the CV of the measurements and
therefore CV calculations were done on the raw data before
normalisation. CV was below 15% for most of the spheroids on
the dose-response curve for APH and Resazurin assays. Volume
had the lowest variability at low concentrations of etoposide,
closely followed by the APH assay. However, the variability of
volume measurements increased significantly in the wells where
cell death was predominant (30–300 mM) making volume mea-
surements less reliable at high etoposide concentrations despite the
washing procedure. It is worth noting that despite the low CV% of
the APH assay compared to Volume determinations and
Resazurin, the precision of the APH IC50 fits was generally lower.
Overall, volume measurements were the best method to study
etoposide activity in foetal brain tissue closely followed by
Resazurin reduction. Volume measurement sensitivity was greatly
improved by washing off debris and dead cells with PBS similarly
to the UW228-3 cells (Figure 9).
Spheroid size reduction and metabolic activity determination
complement each other as they use different mechanisms to
estimate viability and can paint a fuller picture of spheroid health.
When the rate of volume decrease is slower than the change in
metabolic activity it would suggest that the proportion of dead
cells, within the spheroid, is influencing the volume reading or that
cells increase their volume due to treatment. However, a faster rate
of volume decrease compared to resazurin reduction would
indicate apoptosis-induced cell shrinkage without loss of metabolic
Figure 7. Confidence intervals for etoposide IC50 determinations for different assays in UW228-3 cells. The 95% confidence intervals
(CI) for each experiment were plotted against the geometric mean (black dotted line) and 95% CIs (green dotted lines) for all individual experiments
for each assay.
doi:10.1371/journal.pone.0103817.g007
Figure 8. Confidence intervals for etoposide IC50 determinations for resazurin and Volume in neural stem cells. The 95% confidence
intervals (CI) for each experiment were plotted against the geometric mean (black dotted line) and 95% CIs (green dotted lines) for all individual
experiments for resazurin and Volume determinations.
doi:10.1371/journal.pone.0103817.g008
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activity. Indeed a proportion of larger cells with increased
metabolic activity, as described by Chan et al [50] may be present
in our neurospheres assay causing an underestimation of
cytotoxicity in the case of volume and resazurin. Nevertheless
viability estimates for volume and cell numbers were not
statistically different for the most part of the dose-response curve.
While some cells in the spheroids could increase in volume, others
may shrink due to apoptosis and yet another group would detach
from the spheroid bringing volume estimates for viability closer to
cell numbers. Although live cell counts can be viewed as the ‘‘gold
standard’’ for viability determinations in 2D, the extensive
procedure for spheroid dissociation introduces variability out-
weighing the benefits of accuracy. Therefore, based on the lower
variability of IC50 measurements and the similarities with actual
cell numbers, in cases dealing with a new drug delivery strategy for
a particular drug or with drugs with similar mode of action,
volume would be a superior assay able to distinguish smaller
differences in IC50s.
Conclusions
Three-dimensional human cell culture is a useful tool that can
help narrow the gap between preliminary in-vitro studies and in-
vivo experiments that are required for drug development.
Spheroids are cultured just as easily as monolayers in 96-well
ultra-low attachment plates and a suite of assays can be employed
to probe their viability. We have provided an open source ImageJ
macro that automatically measures whole batches of spheroids and
records the results both numerically and as an image. Spheroid
volume was shown to be an excellent predictor for the number of
viable cells in healthy spheroids. It can also be used as a reference
method for cytotoxicity assays where the normalized volume
readings are compared to other ways of estimating cell health. In
this respect, the acid phosphatase assay was tested and its linear
response to cell number in medulloblastoma spheroids of 160–
700 mm validated. It is a simple, quick method for viability
determination that does not require any expensive ingredients and
is high-throughput compatible. However it relies on lysing the cells
in question and needs to be the final assay in a high-content
screening chain. The third assay tested, resazurin reduction, does
not have these shortcomings because it is not toxic to the cells in
the concentrations and exposure times used, it can be performed
multiple times and coupled with other studies. The difference in
metabolic rate between the cells in the periphery and the middle of
the spheroid can account for the lower r squared values of
resazurin data fit compared to the other two methods. Although it
appears inferior to volume determination and APH, we have
demonstrated that metabolic activity can reliably be used in
cytotoxicity screens despite its perceived limitations. The optimal
seeding densities for both cell types were determined by biological
considerations for spheroid size and gradients and were also
benchmarked for Z-factor.0.4, Signal window.2 and Coeffi-
cients of variation,20%. The suite of assays was performed on the
same spheroids and the results compared and validated against the
number of cells in a spheroid using both healthy tissue and
spheroids exposed to a cytotoxic drug. Plate uniformity was
examined for spheroid volume at day 3 and signal variability was
assessed for volume, resazurin and APH assays during the
Figure 9. Phase-contrast microscope images of NSC exposed to increasing concentrations of etoposide. A–C spheroids before PBS
wash. A9–C9- the same spheroids after PBS wash. Control is grown in plain media, concentrations of etoposide on drug treated spheroids shown in
mM, scale bar applies to all panels.
doi:10.1371/journal.pone.0103817.g009
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cytotoxicity screen. After comparing the precision of IC50
determinations for all assays, cell volume and resazurin were
found to perform better than APH and cell counts for both cell
types. As volume, metabolism and acid phosphatase activity can all
be influenced by cytotoxic drugs in a different manner,
multiplexing those assays is the best way to get the true picture
of cellular response. Since our interests lie in improving drug
delivery in medulloblastoma we have only focused on one drug in
this study. A useful future direction would be to explore a library of
compounds which would allow for minimum significance ratio
determination and better characterisation of the assays and cell
response over an array of drugs with different mechanism of action
[56].
Etoposide sensitivity of the UW228-3 medulloblastoma cell line
was carried out in parallel with human foetal brain tissue derived
stem cells (NSC) in order to have a comparison with cells
representing human brain tissue. While the tumours exhibited a
normal four parameter logistic dose-response curve, the NSCs had
a biphasic response. The most likely explanation for this data is the
presence of two sub-populations of cells within the neurospheres
with a different sensitivity towards etoposide. The first sub-
population had a low acid phosphatase activity and was more
susceptible towards cytotoxic action, whereas the second one had a
higher APH activity and was more resistant to topoisomerase
inhibitors. The foetal NSC cells would be expected to have a
relatively high proportion of stem cells. Under 3D culture
conditions and the associated gradients of oxygen and nutrients
the population of early progenitor cells can differentiate into late
progenitors, neurons and glia which would have different rates of
division and different sensitivity to etoposide. The faster dividing
and more sensitive cell population is probably the less-differenti-
ated one. Those undifferentiated cells are responsible for the
growth, development and repair in vivo. While they make up a
higher proportion of the brain in childhood when the brain is still
growing and developing, they are confined to specific locations in
the adult brain and have a supportive role. Establishing the
proportions of stem-like, neural and glial cells that make up the
neurospheres and how those change during etoposide exposure
would bring greater insight into the off-target effects of topoisom-
erase II inhibitors. Furthermore the relative cell type proportions
in the neurospheres could be influenced by changes in the media,
such as EGF and FGF withdrawal that would promote progenitor
differentiation into neurons and glia. Nevertheless, foetal brain
tissue as a whole was more sensitive to etoposide up to
concentrations of 5–10 mM when the neurospheres’ slow decrease
in viability was surpassed by the sharp decline in tumour cell
survival. This is a biorelevant concentration that has been
established to be tolerable in humans thereby inferring some
limited selectivity of free etoposide [57].
Although etoposide is not generally regarded as a neurotoxic
drug [58] there are reports which have demonstrated neurotox-
icity in mice after blood-brain barrier disruption [59–61]. The
heightened sensitivity of a sub-population of the neurosphere cells
to etoposide can be explained by the presence of EGF and FGF in
the culture media which limit differentiation and stimulate
division. In the normal human brain in-vivo, only a small
percentage of the available neural stem cells proliferate whereas
the others are quiescent and may be spared from the effects of the
cytotoxic drugs [62,63]. This study suggests that free etoposide is
not discriminating against actively dividing tumour and stem cells
at concentrations below 10 mM. To enhance selectivity, better
methods for drug delivery are needed to improve the effectiveness
of medulloblastoma chemotherapy. Strategies to enhance the
selectivity of etoposide could be using an etoposide-bearing drug-
delivery system [64–66] that primarily targets tumour tissue or
intrathecal therapy [4] to target leptomeningeal tumour tissue.
This convenient screening method can be implemented with
standard equipment and reagents and can be used for screening
new agents and drug delivery systems targeting CNS tumours. It
offers the opportunity to compare the effect of drug upon the
tumour and brain thereby comparing efficacy against toxicity,
enhancing the bio-relevance to human tumours in clinical practice
[10,59,67,68]. The correlation with previously reported experi-
mental and clinical studies [57,60–63] and the practical conve-
nience of this assay procedure suggest that it should be considered
as a possible replacement for some animal testing experiments
dealing with drug efficacy, particularly in brain tumour types
relevant to childhood.
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Supporting Information
Figure S1 Plate uniformity assessment for volume and
diameter of spheroids before and after outlier removal.
NSC and UW populations are marked according to experiment
number. All populations, with the exception of UW1, had a
normal distribution according to the D’Agostino-Pearson omnibus
K2 test after outlier elimination using Prism’s ROUT algorithm.
(TIF)
Figure S2 UW spheroids treated with etoposide.
(TIF)
Figure S3 NSC spheroids treated with etoposide.
(TIF)
Figure S4 Methods of combining different IC50 deter-
minations between experiments for UW228-3 cells. Data
was subjected to an F-test to find a common curve that described
all runs (Prism’s F-test); The mean of logIC50 values was used in
the geometric mean method and combining all normalised
readings from different runs together was employed in the pooling
method. Error bars are 95% Confidence intervals. The * in
Volume F-testing means that the calculated IC50 values were
statistically different between runs according to the extra-sum-of-
squares F-test.
(TIF)
Figure S5 Plate uniformity for cytotoxicity tests. Z-
factors for Volume- A and B; Acid phosphatase- C and D; and
Resazurin- E and F.
(TIF)
Figure S6 Coefficient of variation for different assays of
etoposide treated plates. A and B- Volume; C and D-APH; E
and F-Resazurin.
(TIF)
Macro S1 ImageJ macro automating size measure-
ments for a folder of phase-contrast spheroid images.
(DOCX)
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